


PSMA-IN-1

Cat. No.:	HY-149297
Molecular Formula:	C ₆₆ H ₈₀ N ₁₀ O ₂₀
Molecular Weight:	1333.4
Target:	PSMA
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	PSMA-IN-1 (compound 23) is an inhibitor of PSMA with a K _i value of 2.49 nM. PSMA-IN-1 inhibits tumor growth with high selectivity and specificity in PSMA+ xenograft models. PSMA-IN-1 is a NIR probe (λ _{EX} : 620 nm; λ _{EM} : 670 nm) used for tumor disappearance. PSMA-IN-1 can be used for research on prostate cancer ^[1] .								
In Vivo	<p>PSMA-IN-1 (0.33 mg/kg, i.v., one time) is a NIR probe (λ_{EX}: 620 nm; λ_{EM}: 670 nm) used for tumor disappearance, and acquires images at different time points after injection (2, 4, 8, 12, 24, and 48 h)^[1].</p> <p>PSMA-IN-1 (0.33 mg/kg, i.v., one time) inhibits tumor growth with high selectivity and specificity in the BALB/C nude mice tumor bearing model constructed with 22Rv1^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>22Rv1 xenograft models in BALB/C nude mice^[1]</td> </tr> <tr> <td>Dosage:</td> <td>0.33 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intravenous injection (i.v.), sacrificed at 55 h post-injection</td> </tr> <tr> <td>Result:</td> <td>Increased TNR (tumor-to-normal tissue ratio) values from 3.20 at 2 h to 6.27 at 48 h.</td> </tr> </table>	Animal Model:	22Rv1 xenograft models in BALB/C nude mice ^[1]	Dosage:	0.33 mg/kg	Administration:	Intravenous injection (i.v.), sacrificed at 55 h post-injection	Result:	Increased TNR (tumor-to-normal tissue ratio) values from 3.20 at 2 h to 6.27 at 48 h.
Animal Model:	22Rv1 xenograft models in BALB/C nude mice ^[1]								
Dosage:	0.33 mg/kg								
Administration:	Intravenous injection (i.v.), sacrificed at 55 h post-injection								
Result:	Increased TNR (tumor-to-normal tissue ratio) values from 3.20 at 2 h to 6.27 at 48 h.								

REFERENCES

[1]. Wang X, et al. Design and Characterization of Squaramic Acid-Based Prostate-Specific Membrane Antigen Inhibitors for Prostate Cancer. J Med Chem. 2023 May 25;66(10):6889-6904.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA